---
schema_version: "secwatch.filing_event.v1"
accession: "0001799191-24-000028"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:02:34.527742+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TOI Q3 revenue up 22% to $99.9M; net loss narrows to $16.1M, adjusted EBITDA -$8.2M

## Summary
- Revenue $99.9M (+21.8% YoY), driven by dispensary revenue surge of 79.9%.
- Gross profit $14.4M (-10.1% YoY); SG&A reduced 6% to $26.6M.
- Net loss $16.1M ($0.18 EPS) vs $17.4M loss in Q3 2023.
- Adjusted EBITDA -$8.2M vs -$5.3M in prior year period.
- Board completed strategic review; elected to continue current plan.

## SEC filing metadata
- accession: 0001799191-24-000028
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000179919124000028/0001799191-24-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000179919124000028/toi-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001799191-24-000028
- JSON: https://secwatch.observer/filing/0001799191-24-000028.json
- Plain text: https://secwatch.observer/filing/0001799191-24-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.